Carcinoma, Hepatocellular: all 3,249 studies

Page 2 of 33. Open to participants first (974), then studies with results posted, then the rest; newest registration first within each.

• HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)RecruitingNCT07594340Phase 3
• 68Ga-NYM207 PET/CT Imaging in Hepatocellular CarcinomaRecruitingNCT07590336Phase 1/2
• Defining the Ablative Dose for Y-90 TARERecruitingNCT07586046Phase 2
• AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)Not yet recruitingNCT07584317
• The DoHAICs Study Expansion PhaseNot yet recruitingNCT07584018Phase 2
• A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid TumorsNot yet recruitingNCT07583316Phase 1
• Impact of the Procurement Technique on Outcomes After Liver TransplantationNot yet recruitingNCT07582978
• Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment DecisionsNot yet recruitingNCT07582419
• YMN-A02 for Advanced Primary Hepatocellular Carcinoma.Not yet recruitingNCT07580261Phase 1
• Social Determinants of Health HCC TrialNot yet recruitingNCT07568457Not applicable
• Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and ImmunotherapyNot yet recruitingNCT07565415Phase 2
• SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical IndomethacinRecruitingNCT07560566Phase 2
• Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaRecruitingNCT07560488Phase 2
• Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid TumorsNot yet recruitingNCT07558200Phase 1
• Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesNot yet recruitingNCT07557914Phase 2
• 18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsRecruitingNCT07557225Not applicable
• Outcomes After Liver and Biliary Resection at a High-Volume CenterNot yet recruitingNCT07556835
• Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical ResectionNot yet recruitingNCT07553767Early Phase 1
• A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Phase 1/2
• Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related CirrhosisNot yet recruitingNCT07544121Not applicable
• Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 TrialNot yet recruitingNCT07543783Phase 2
• Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07543510Not applicable
• AI-Assisted Staging and Treatment Decision-Making for Hepatocellular CarcinomaRecruitingNCT07538882
• Denosumab Strategy for Liver Cancer With Bone MetastasesNot yet recruitingNCT07537972Phase 2
• Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic MetastasesNot yet recruitingNCT07537959Not applicable
• Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver CancerNot yet recruitingNCT07537946Phase 3
• Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted TherapyNot yet recruitingNCT07537777Phase 2
• A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular CarcinomaNot yet recruitingNCT07535840Not applicable
• Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsRecruitingNCT07523529Phase 1/2
• Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular CarcinomaNot yet recruitingNCT07522411Phase 1/2
• A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCCRecruitingNCT07521852Phase 2
• Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow MarginNot yet recruitingNCT07518706Phase 2
• A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence RiskNot yet recruitingNCT07515469Phase 2
• Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma PatientsNot yet recruitingNCT07514455Phase 2
• Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC TrialNot yet recruitingNCT07514429Phase 2
• Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaNot yet recruitingNCT07511504Phase 2
• Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular CarcinomaRecruitingNCT07495735
• Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)Not yet recruitingNCT07495579Phase 2
• A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical ResectionRecruitingNCT07495215Phase 1/2
• Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line ImmunotherapyRecruitingNCT07493668Phase 2
• An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular CarcinomaRecruitingNCT07493044Phase 1
• A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.RecruitingNCT07490262Phase 2/3
• GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence MonitoringNot yet recruitingNCT07489768
• Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular CarcinomaNot yet recruitingNCT07487402Early Phase 1
• Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 InhibitorsRecruitingNCT07485114
• Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor ThrombusRecruitingNCT07483359Phase 2
• Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled StudyNot yet recruitingNCT07481032Not applicable
• MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)RecruitingNCT07479485Phase 1/2
• Scout Dose of Resin MicrospheresRecruitingNCT07476651Not applicable
• A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Phase 3
• Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral CirrhosisRecruitingNCT07469319Not applicable
• cfDNA Methylation for Liver Cancer Recurrence DetectionRecruitingNCT07466602
• PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-ImmunotherapyRecruitingNCT07463248Phase 2
• Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver ResectionNot yet recruitingNCT07461675Phase 3
• THIO and Cadonilimab in Resectable Hepatocellular CarcinomaRecruitingNCT07446257Early Phase 1
• Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic HypertrophyRecruitingNCT07445412
• Affordable Made-in-India Microspheres for Liver Cancer TherapyNot yet recruitingNCT07436988Phase 1
• Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and ImmunotherapyRecruitingNCT07436845
• Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics ApproachesRecruitingNCT07432347
• Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With BulvertideRecruitingNCT07429864
• Histotripsy for Ablation of Liver Tumours in AsiaRecruitingNCT07428356Not applicable
• A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCCRecruitingNCT07422753Phase 2
• A Phase 1 Study of the Safety and Tolerability of CTX-10726RecruitingNCT07419841Phase 1
• Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep LearningRecruitingNCT07417800
• Adjuvant TACE in HCC With High-risk Recurrence FactorsRecruitingNCT07417397Phase 3
• Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular CarcinomaNot yet recruitingNCT07414433
• Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaRecruitingNCT07413354Phase 2
• Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCCNot yet recruitingNCT07412054Phase 2
• Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular CarcinomaRecruitingNCT07410715
• Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid TumorsRecruitingNCT07410494Phase 1/2
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT StudyRecruitingNCT07405086Phase 4
• Phase II Trial of Immunonutrition in HepatectomyRecruitingNCT07395635Not applicable
• A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT07392866Phase 2/3
• MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.RecruitingNCT07391839Phase 1
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabRecruitingNCT07391670Phase 1
• SBRT Versus Surgical Resection for Small HCCRecruitingNCT07381660Phase 3
• The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related ToxicitiesRecruitingNCT07381634Phase 2
• Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular CarcinomaRecruitingNCT07378709
• TheraSphere Japan Pre-Market StudyRecruitingNCT07377487Not applicable
• A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid TumorsRecruitingNCT07376707Phase 1
• Sapu003 in Advanced mTOR-sensitive Solid TumorsRecruitingNCT07369505Phase 1
• MR 7700 Multinuclear Application Clinical StudyNot yet recruitingNCT07368049Not applicable
• A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07368023
• NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line TherapyRecruitingNCT07365930
• A Phase I Study of CREPT-618 in Locally Advanced HCCRecruitingNCT07364357Phase 1
• Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor ThrombusNot yet recruitingNCT07363512Phase 2
• Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaRecruitingNCT07359586
• Prediction of Complications in Hepatic TumorsNot yet recruitingNCT07358975Phase 4
• Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular CarcinomaNot yet recruitingNCT07356037Phase 3
• Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular CarcinomaNot yet recruitingNCT07352345Early Phase 1
• A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular CarcinomaRecruitingNCT07351669
• First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Phase 1
• RAdiation SEgmentectomy With REsin Microspheres (RASEREM) StudyRecruitingNCT07345247
• SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint InhibitorsRecruitingNCT07341321
• Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence FactorsRecruitingNCT07337460Phase 2
• Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence FactorsRecruitingNCT07337421Phase 2
• A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver CancerNot yet recruitingNCT07337031Not applicable
• Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)RecruitingNCT07331883Phase 2
• ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Phase 2
• Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular CarcinomaRecruitingNCT07324824Phase 2

← Carcinoma, Hepatocellular overview